Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
暂无分享,去创建一个
[1] M. Koch,et al. Survival and predictors of death in dialysed diabetic patients , 1993, Diabetologia.
[2] Martin Schumacher,et al. Sample sizes for clinical trials with time-to-event endpoints and competing risks. , 2005, Contemporary clinical trials.
[3] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[4] J. Bragg-Gresham,et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] John Simes,et al. Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.
[6] W. März,et al. Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.
[7] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[8] J. Armitage,et al. Cardiovascular outcomes among participants with diabetes in the recent large statin trials , 2004, Current opinion in lipidology.
[9] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[10] B. Cheung,et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. , 2004, British journal of clinical pharmacology.
[11] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[12] S. Prichard. Impact of dyslipidemia in end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.
[13] T. Meyer,et al. Urämische Patienten - späte Überweisung, früher Tod , 2003 .
[14] N. Lameire,et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] W. Hörl,et al. [Uremic patients--late referral, early death]. , 2003, Deutsche medizinische Wochenschrift.
[16] Peter Stenvinkel,et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.
[17] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[18] K. Iseki,et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.
[19] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] K Doqi,et al. clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .
[21] B. Kestenbaum,et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.
[22] Colin Baigent,et al. Premature cardiovascular disease in chronic renal failure , 2000, The Lancet.
[23] W. März,et al. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis , 1999 .
[24] R. Foley,et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[25] K. Shimokata,et al. Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl)lysine in aortas of hemodialysis patients. , 1998, Cellular and molecular biology.
[26] E. Ritz,et al. Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.
[27] F. Kronenberg,et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.
[28] M Nauck,et al. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. , 1995, Clinical chemistry.
[29] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[30] E. Ritz,et al. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. , 1993, Nephron.
[31] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.